WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information

The WHODrug medicinal information dictionary is a worldwide source of global medicinal information with the aim to facilitate the coding of medications in clinical trials as well as identification of medication-related problems when monitoring patient safety, thereby supporting the development and usage of effective and safe medications. WHODrug contains individual trade names, active ingredients and additional information such as marketing authorisation holder, country of sale, pharmaceutical form and strength. All related medications are linked using a structured WHODrug alphanumeric code, connecting trade names and variation of the ingredient with the active moiety of the ingredient. Medications in WHODrug are classified using the ATC system and clustered into Standardised Drug Groupings, to allow for grouping of medications with one or more properties in common. The built-in data structure and the classification of medications in WHODrug facilitate various ways of aggregating medications for identification and analysis of possible adverse drug reactions. The different information levels in WHODrug are used to explore the relationship between a medication or a class of medications and an adverse event. By using WHODrug in clinical trials and post-marketing safety, accurate and standardised medication information can be achieved globally and allow easy information exchange. To meet the demands of WHODrug users from the pharmaceutical industry, academia and regulatory authorities, it is relevant to keep the dictionary comprehensive, validated and constantly updated on a global scale.

[1]  L. Fauchier,et al.  Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan , 2018, British journal of clinical pharmacology.

[2]  N. Vargesson Thalidomide‐induced teratogenesis: History and mechanisms , 2015, Birth defects research. Part C, Embryo today : reviews.

[3]  Zhengwu Lu,et al.  Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs. , 2010, Contemporary clinical trials.

[4]  I. Edwards,et al.  Paediatric safety signals identified in VigiBase: Methods and results from Uppsala Monitoring Centre , 2019, Pharmacoepidemiology and drug safety.

[5]  G. N. Norén,et al.  Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports , 2019, Drug Safety.

[6]  G. Jaya Nair Ensuring quality in the coding process: A key differentiator for the accurate interpretation of safety data , 2013, Perspectives in clinical research.

[7]  S. Pal,et al.  WHO programme for international drug monitoring , 2013 .

[8]  J. Venulet,et al.  Drug Recording and Classification by the WHO Research Centre for International Monitoring of Adverse Reactions to Drugs , 1974, Methods of Information in Medicine.

[9]  J. Venulet,et al.  WHO’s International Drug Monitoring — The Formative Years, 1968–1975 , 2010, Drug safety.

[10]  Antoni F. Z. Wisniewski,et al.  Recommendations for the Use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR , 2019, Drug Safety.

[11]  M. Lindquist VigiBase, the WHO Global ICSR Database System: Basic Facts , 2008 .

[12]  Organización Mundial de la Salud Guidelines for ATC classification and DDD assignment , 1996 .

[13]  G. N. Norén,et al.  Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites , 2015, Drug Safety.

[14]  Sarah Watson,et al.  Desogestrel and panic attacks – a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports , 2018, British journal of clinical pharmacology.

[15]  Deven Babre,et al.  Medical Coding in Clinical Trials , 2010, Perspectives in clinical research.